Zobrazeno 1 - 6
of 6
pro vyhledávání: '"D. Hammann"'
Autor:
Anton Stangelberger, Patricia Armatis, Brian D. Hammann, Ren Zhi Cai, Andrew V. Schally, Benjamin Baker, Celia A. Kanashiro, Jozsef L. Varga, Marta Zarandi
Publikováno v:
European Journal of Cancer. 41:2735-2744
Bombesin/gastrin-releasing peptide (BN/GRP) antagonists RC-3940-II and RC-3940-Et, and growth hormone-releasing hormone (GHRH) antagonists MZ-J-7-118 and RC-J-29-18 inhibit the growth of human androgen-independent PC-3 and DU-145 prostate cancers in
Publikováno v:
International Journal of Cancer. 112:570-576
We investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone and in combination with bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC-3940-II on the growth of H-69 human small cell lung carcinoma (SCLC) xenogra
Publikováno v:
International Journal of Oncology.
New therapeutic strategies are necessary to improve the treatment of lung cancer. We investigated the effects of bombesin/gastrin-releasing peptide (GRP) antagonist, RC-3940-II, and growth hormone-releasing hormone (GHRH) antagonists, MZ-J-7-114 and
Autor:
Jörg B. Engel, Andrew V. Schally, Brian D. Hammann, Gabor Halmos, Attila Nagy, Gunhild Keller
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 11(6)
Purpose: To determine whether the cytotoxic analogue of bombesin/gastrin-releasing peptide (GRP) AN-215 can inhibit the in vivo growth of four human ovarian cancer cell lines. AN-215 consists of 2-pyrrolinodoxorubicin (AN-201), a superactive derivati
Autor:
Gabor Halmos, Brian D. Hammann, Andrew V. Schally, Attila Nagy, Gunhild Keller, Jörg B. Engel
Publikováno v:
International journal of cancer. 114(5)
The cytotoxic analogue of somatostatin, AN-238, consisting of 2-pyrrolinodoxorubicin (AN-201), a superactive derivative of doxorubicin (DOX), linked to somatostatin analogue carrier RC-121 binds with high affinity to receptors for somatostatin and ca
Autor:
Gabor Halmos, Celia A. Kanashiro, Marta Zarandi, Andrew V. Schally, Brian D. Hammann, Jozsef L. Varga
Publikováno v:
Cancer letters. 226(2)
Effects of in vivo treatment with antagonists of growth hormone-releasing hormone (GHRH), JV-1-65 and MZ-J-7-110, and bombesin/gastrin-releasing peptide antagonist RC-3940-II, on the EGF receptor (EGFR) family, were investigated in H-69 SCLC. Tumors